KPMG: 94% of Life Sciences CEOs to Expand Workforce Over the Next 3 Years
In recent years, the biopharma industry has frequently made headlines for layoffs as companies, both large and small, implemented cost-cutting measures and restructuring plans. Over the past 10 days alone, reports have emerged of workforce reductions at major firms, including Bristol Myers Squibb, Novartis, Lexicon Pharmaceuticals, Johnson & Johnson, Gilead...